Published on in Vol 5, No 2 (2017): Apr-Jun

Virtual Reality as an Adjunct Home Therapy in Chronic Pain Management: An Exploratory Study

Virtual Reality as an Adjunct Home Therapy in Chronic Pain Management: An Exploratory Study

Virtual Reality as an Adjunct Home Therapy in Chronic Pain Management: An Exploratory Study

Authors of this article:

Bernie Garrett1 Author Orcid Image ;   Tarnia Taverner1 Author Orcid Image ;   Paul McDade2 Author Orcid Image

Original Paper

1School of Nursing, University of British Columbia, Vancouver, BC, Canada

2Faculty of Science, University of British Columbia, Vancouver, BC, Canada

*these authors contributed equally

Corresponding Author:

Bernie Garrett, RN, PhD

School of Nursing

University of British Columbia

T 201 2211 Wesbrook Mall

Vancouver, BC, V6T 2B5


Phone: 1 604 753 8942

Fax:1 604 822 7466


Background: Virtual reality (VR) therapy has been successfully used as an adjunct therapy for the management of acute pain in adults and children, and evidence of potential efficacy in other health applications is growing. However, minimal research exists on the value of VR as an intervention for chronic pain.

Objective: This case series examined the value of VR to be used as an adjunctive therapy for chronic pain patients in their own homes.

Methods: An exploratory approach using a case series and personal interviews was used. Ten chronic pain patients received VR therapy for 30 min on alternate days for 1 month. Pre- and postexposure (immediately afterwards, 3 h, and at 24 h) pain assessment was recorded using the Numerical Rating Scale (NRS), and weekly using the Brief Pain Inventory (BPI) and Self-completed Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS). Terminal semistructured personal interviews with the patients were also undertaken.

Results: Of the 8 patients who completed the study, 5 of them reported that pain was reduced during the VR experience but no overall treatment difference in pain scores postexposure was observed. VR was not associated with any serious adverse events, although 60% of patients reported some cybersickness during some of the experiences.

Conclusions: Of note is that the majority of these study participants reported a reduction in pain while using the VR but with highly individualized responses. One patient also reported some short-term improved mobility following VR use. Some evidence was found for the short-term efficacy of VR in chronic pain but no evidence for persistent benefits.

JMIR Med Inform 2017;5(2):e11



Research on virtual reality (VR) dates back to the early 1980s [1], but the potential for mainstream use has only recently been realized. Some successes have been reported in the use of VR in the treatment of acute pain as an adjunctive method for pain control [2-7]. Clinical studies exploring its use for chronic pain remain minimal [8-10]. Results have been hopeful, but some used artificially induced pain in healthy adults rather than actual chronic pain patients; thus, findings may not be clinically comparable [8]. Nevertheless, the value of VR in chronic pain management remains an area of potentially high impact research. In Canada, chronic pain is a significant health issue with 18.9% of adult Canadians suffering from chronic persistent pain [11]. Chronic pain persists as a complex phenomenon affecting millions of Canadians every day [11-15]. Chronic pain patients also often find their pain experiences persist despite medical interventions, and those affected frequently suffer from additional decreases in psychosocial health and activity restriction [16-17].

Cognitive factors are well-known to affect perceptions of pain [18]. Currently, VR environments are hypothesized to reduce pain via cognitive attentional and distractive mechanisms, although the exact mechanisms remain unclear [19-25]. The use of VR might act directly and indirectly on pain perception in a number of ways by altering signaling pathways involving attention, emotion, concentration, memory, touch, and the auditory and visual senses. VR interventions appear to reduce pain sensitivities by altering the sense of personal presence to that of being in new virtual environment, changing the sensory, affective, and cognitive features of the experience and altering the subjective perception of pain [26,27]. Therefore, the potential value of VR to help mediate chronic pain is an important area for exploration. The primary aims for this exploratory study were to identify any changes from baseline pain scores and in reported pain experiences using VR, and establish whether VR can be practically and safely used at home. Secondary aims included identifying any weekly pain score changes, any adverse effects [28], effects on function, and any preferences in type of VR experience. In addition, the study was undertaken to evaluate feasibility and establish practical methods to research VR interventions for chronic pain.


A mixed-methods pilot case-series approach was used. The quantitative a priori hypotheses tested were that for patients with established chronic pain treated at home: (1) exposure to VR for 30 min 3 times a week would decrease pain scores from their preexposure baseline, and (2) exposure to VR sessions 3 times a week would lead to decreased weekly pain scores over a month. The qualitative aspects of the study examined patient’s perceptions of their pain while using VR, if they observed any practical application of safety issues in using VR or experienced any adverse effects. Also, their VR experience preferences, and if they noted any functional or quality-of-life improvements during the study were examined.

Sample Selection and Recruitment

Prior to recruitment, a review of the proposal was undertaken by the UBC Clinical Research Ethics Board and approval granted. A purposeful nonprobability convenience sample of 10 adult patients with a diagnosed chronic pain condition for at least six months were recruited by Web-based invitations from 2 sources; PainBC and the People in Pain Network. Both are charitable support organizations, based in British Columbia. Interested patients were sent further information and a telephone interview by a member of the research team was conducted to answer the patients’ questions and screen them against specific inclusion and exclusion criteria (see Textboxes 1 and 2). Suitable patients were then sent an informed consent form to be signed and returned on installation of the VR equipment (with a duplicate copy provided for them to retain).

Inclusion criteria for the study.

• ≥18 years

• Have had a chronic pain diagnosis for 6 months or longer

• Score a maximum of ≥4 on the NRS pain scale daily

• Have desk space at home for the VR headset and accompanying computer system

• Able to understand the English language, and read and write English

• Able to wear a VR HMD (head-mounted display) and move head in cervical rotation, extension, and flexion

• sufficient fine motor control to operate a joystick/game controller

Textbox 1. Inclusion criteria for the study.
Exclusion criteria for the study.

• Individuals who have cognitive impairment or inability to control a basic computer VR interface, or complete questionnaires

• Susceptibility to motion sickness or cyber-sickness (LaViole 2001)

• Susceptibility to claustrophobia

• History of susceptibility to seizures

Textbox 2. Exclusion criteria for the study.


A home-based VR intervention was selected for the study. First, for practicality, as many of these patients also had mobility concerns and it was not economical to offer transportation to a hospital or lab and back again several times a week. Second, commercial VR systems would need to be suitable and easy to use at home, if they proved efficacious in the treatment of chronic pain. The VR hardware used was identical for each patient, and consisted of a high-end personal computer running the VR applications with an Oculus Rift DK2 1100 field of view (FOV) stereoscopic head-mounted display (HMD) with a resolution of 960 × 1080 pixels per eye.

As there were no VR experiences validated in the context of chronic pain, one of the project’s aims was to explore whether patients expressed preferences for different VR environments. Four categories of VR experience were devised, and VR applications were purposefully selected and tested in advance for potential efficacy by the researchers for use in each of the 4 weeks of the study. In week 1, the participants undertook passive VR experiences where they simply travelled through a VR environment. These included a virtual Iceland, and a boat ride through an artistic experience (Senza Peso). In the second week, mindfulness and meditative introversion focused VR applications were used, as these have been associated with pain control in other studies [29,30]. These experiences involved flying through 3D mandalas, or experiences that altered the user’s environment depending where they looked (Sightline). In the third week, active exploratory VR environments were used, where the participant could explore a new environment at will (an underwater environment, the solar system, and a natural environment). In the final week, active problem-solving experiences were used (eg, game type environments requiring participants to solve 3D puzzles). These different applications allowed for comparison of the VR environments in terms of any reported specific effects on patient’s pain experiences and side effects, and also prevented boredom with the VR experiences available at the time. An identical protocol of specific VR experiences to be used for 30 min on every other day of the study was given to each patient (see Figure 1). A simple computer menu system was devised so that patients could easily start each VR application on the appropriate day in sequence (as per protocol). Daily VR activity was logged, with arrest from VR at weekends.

Three sets of equipment were used concurrently with different patients, and then moved on to the next patients who had volunteered on a previously arranged schedule. The equipment was installed in the patients’ home with a 90-min training session on how to use the VR and perform data collection procedures. Patients were also assessed as being able to navigate the VR experiences and use the equipment comfortably at the end of this. During the study time patients also had access to a member of the research team by telephone and email for trouble shooting and to discuss any issues associated with the study.

Given an absence of prior work with VR and chronic pain, an initial exposure to 12 therapeutic sessions of 30 min was identified as reasonable to explore the clinical effects of VR initially. VR research in acute pain settings was usually of 15-30 min duration [2] and in associated pain hypnotherapy studies that used 4-6 sessions had less success whereas studies that had offered 8-12 sessions with lengths of treatment exposure between 30 and 40 min established positive results [31,32].

Figure 1. VR (virtual reality) intervention protocol and sequence.
View this figure

Instruments: Quantitative Tools

To ensure the multidimensional aspects of chronic pain experienced by individuals were adequately measured, various tools were selected that addressed different aspects of chronic pain. These were self-recorded by patients in a supplied binder.

Pre- and Postexposure NRS Scores

Participants were asked to self-rate and record their pain intensity in a diary using the NRS immediately before and after the intervention and at 6 and 24 h postintervention (it was impractical to record pain during the VR experience as this would have proved disruptive to the experience). These measurement points supported the capture of any residual therapeutic effects or trends following the intervention. The NRS meets the IMMPACT group recommendations for using a global impression of change question [33,34].

Weekly Pain Trends: The Brief Pain Inventory (BPI) and Short Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS)

The BPI and the S-LANSS were used initially (as a baseline) and then at the end of each week of therapy to capture more detailed pain assessment data (giving scores recorded at 5 different time points). The BPI is a validated tool that has been used in numerous studies investigating pain [35-37]. The S-LANSS was specifically designed to measure the pain qualities associated with neuropathic pain and treatment effects. It is a quick to use self-reporting scale consisting of 12 distinct questions, which ask about the intensity and quality of the patients’ pain [38].

Cybersickness Reporting Form

Cybersickness is a well-documented side-effect of VR experiences [28,39-41]. It is the tendency for some users to display symptoms analogous to motion sickness both during and after the VR experience. It is distinct from motion sickness, in that the user is normally stationary but has a compelling sense of self-motion through moving visual imagery. A simple guide to avoid cybersickness and self-reporting form was provided for patients to record any episodes on a weekly basis, indicating the experiences that had led to the episode, onset and duration, any factors that alleviated the sickness, and also any departures from the protocol provided.

Instruments: Qualitative Tools

Initial Individual Interviews

A short semistructured personal interview with each patient was executed at the start of the study by a researcher to capture basic biographic information from participants and a pain history (eg, ethnicity, age, gender, and prior VR and computer gaming experience; pain history: cause, duration, onset, nature, treatment history, and current pharmacological and other interventions used for pain).

Terminal Individual Interviews

An audiotaped 30-min semistructured personal interview was undertaken at the end of the study by a researcher during the final visit to collect the VR equipment. The interview was designed to capture the patient’s perceptions of the value of the VR interventions in the management of their pain, their overall impressions of the experience, and any adverse effects.

Data Analysis

Quantitative data were explored for any differences in the average pain scores for the VR intervention at each time point to analyze for any indications of changes in pain immediately following the VR experience, and at 6 and 24 h after exposure, and for cybersickness. Descriptive univariate statistics were analyzed to support a preliminary understanding of the impact of VR on an individual’s pain experience and nature of the data obtained. A simple initial pre-post exposure NRS analysis was then undertaken using a Wilcoxon matched pairs test. For the BPI and S-LANSS scores, a Freidman test (the nonparametric alternative to the one-way repeated measure ANOVA) was undertaken to explore for any trends evident over the whole month using SPSS 23 statistical software (IBM).

Qualitative data were transcribed from the original sources into Nvivo 7.0 qualitative analysis software. It was analyzed using an interpretive-description (ID) approach for an open exploration of participant’s experiences to further understand the perceptions associated with the use of VR and any impact on their chronic pain. ID assumes preexisting theoretical knowledge, and that clinical patterns exist, and rather than trying to avoid preconceptions in the analysis, coding proceeds on the basis that no matter how participatory and collaborative the analytical method is, it will finally be the researcher who determines what data are significant [42,43]. An ID approach allowed for an inductive descriptive analysis of the phenomena, using iterative readings of the combined qualitative data and coding by 2 independent members of the research team. Analyses were then merged to establish key thematic elements, patterns, and theory associated with the patient’s experiences [42].

Sample Characteristics

As is common with chronic pain studies, the study encountered attrition and 8 patients (n=8, 33% attrition) completed the full study protocol, and only 6 of these consented to post experience interviews [44,45]. Reasons for discontinuation were not required, although one indicated it was due to cybersickness. The patients’ pain conditions and histories are summarized in Table 1.

Table 1. Participant characteristics. All participants were unemployed, had high-school graduate education levels, and good computer literacy.
IDAgeGenderPain diagnosisPain treatment history
0148FemaleLow back and knee pain following traumatic injury 6 years ago.Pharmacological: Acetaminophen & Codeine (Tylenol 3), Oxycodone & Acetaminophen (Percocet), Gabapentin, Ibuprofen, Diclofenac, Oxycodone.

Reported daily NRS score: 4-6Surgical: Right knee replacement.

Other: Physiotherapy, Occupational therapy, Intramuscular Stimulation (IMS)

0263FemaleArachnoiditis and low back pain following traumatic injury 4 years ago.Pharmacological: Acetaminophen & Codeine (Tylenol 3), Ibuprophen, Pregabalin, Gabapentin, Cortisone injection, Ketamine, Fentanyl patches, Hydromorphone.

Reported daily NRS score: 4-7Surgical: Microdiscectomy, Nerve block.

Other: Physiotherapy, Chiropractic

0466MaleIlioinguinal neuralgia following hernia repair 14 years ago. Ankylosing Spondylitis over the last 6 years.Pharmacological: Acetaminophen & Codeine (Tylenol 3), Ibuprophen, Pregabalin, Gabapentin, Ketamine, Methadone, Lignocaine (topical), Oxycodone.

Reported daily NRS score: 4-8Surgical: Inguinal surgical mesh removal and inguinal neurectomy.

Other: Physiotherapy, Yoga

0550MaleCervical spine and shoulder pain following traumatic injury 20 years ago.Pharmacological: Gabapentin, Clonazepam, Nabilone, Oxycodone, Magnesium Injection, Buprenorphine patches.

Reported daily NRS score: 5-8Other: Physiotherapy, Occupational Therapy, Massage, Acupuncture, Water Therapy, Myofascial Release (MFR)

0871FemaleChronic hip & lower back pain for 20 years from strain caused through professionally playing classical guitar for 30 years.Pharmacological: Acetaminophen & Codeine (Tylenol 3), Ibuprophen, Pregabalin.

Reported daily NRS score: 4-8Other: Meditation, Naturopathy (prescribed Turmeric)

0931FemaleComplex regional pain syndrome (Type 2) secondary to thrombosis and multiple embolism 6 years agoPharmacological: Acetaminophen & Codeine (Tylenol 3), Naproxen, Cyclobenzaprine, Gabapentin, Hydromorphone, Pregabalin, Fentanyl patches.

Reported daily NRS score: 6-9Other: Physiotherapy, Massage Therapy, Intramuscular Stimulation (IMS)

1043FemaleMigraine headaches and small fiber myopathy following traumatic injury and resulting brain lesion when 7 years old.Pharmacological: Topiramate, Pregabalin, Cannabis vaporizer and Buprenorphine patch.

Reported daily NRS score: 5-7Other: Acupuncture, Chiropractic, Massage therapy

1136FemaleLow back pain and myofascial pain following traumatic injury 8 years agoPharmacological: Acetaminophen & Codeine (Tylenol 3), Ibuprofen, Baclofen, Lidocaine/Ketamine cream, Gabapentin, Pregabalin, Lidocaine injection, Tramadol Reported daily NRS score: 5-8 & Acetaminophen (Tramacet).

Other: Physiotherapy, Occupational Therapy, Yoga, TENS

Quantitative Analysis

A descriptive statistical exploration of the various pain scores confirmed the data were not normally distributed. Univariate comparison of the mean NRS pre-post test scores demonstrated a slight decrease in pain for most interventions (see Figure 2), although for one intervention (#10) a slight increase in pain was also observed. This likely reflected user frustration with the Subnautica prerelease app, which had not yet implemented game-controller functionality, so participants had to move around using keyboard controls, which was difficult with an HMD on. No reduction in NRS scores 6 and 24 h later was evident. Furthermore, a Wilcoxon Matched Pairs Signed Ranks test for means for each VR intervention demonstrated no significant effect between pre- and postexposure for NRS scores (see Table 2). Given the lack of any significant pre-post exposure effects, no further exploration of NRS scores was performed. The Friedman test run on the BPI and SLANNS scores as repeated measures for each participant at the end of each week also indicated no statistically significant difference in the pain reported over the 4 weeks. BPI Worst Pain: x2=1.6, P=.82 BPI Average Pain: x2=5.2, P=.27; BPI Least Pain: x2=4.6, P=.20. BPI Pain Now: x2=2.9, P=.57. S-LANSS x2= 1.0, P=.91. As no significant findings were obtained, no further post hoc analysis was performed.

Table 2. NRS scores pre-post VR exposure Wilcoxon signed ranks test.
ValuePost1 - Pre1Post2 - Pre2Post3 - Pre3Post4 - Pre4Post5 - Pre5Post6 - Pre6Post7 - Pre7Post8 - Pre8Post9 - Pre9Post10 - Pre10Post11 - Pre11Post12 - Pre12
Asymptotic Significance

aThe sum of negative ranks equals the sum of positive ranks.

bBased on positive ranks.

Qualitative Analysis

Four major thematic areas emerged from the interview analysis: design of the VR experiences, efficacy of VR for chronic pain, limits of the VR technology, and practicality of use as an adjunctive therapy (see Table 3). The subthemes evident in these are described below together with participant quotes.

There was a distinct difference in participants’ perceptions of the value of VR environments designed to be interactive versus those designed to promote relaxation. Half of the interviewees believed that the interactive experiences were more beneficial. For example:

The space one too, when you’re exploring and you’re driving, I loved that one too. I thought that was so much fun, I love the ones when you using your brain, and you’re actually trying to do stuff, I enjoyed those more, but when I was done, I didn’t even notice.
[Participant #10]
…because then you are actually immersed in it, whereas some of the ones you felt like even though it was 3D or whatever, you weren’t really immersed yeah you were a recipient of the experience, but the ones that made you think and do and that and react were more immersive and then the more immersive it is the more it worked.
[Participant #1]

Two participants reported they actively disliked the relaxation-based VR experiences:

I didn’t feel that um, I didn’t sense that just floating over Iceland or um, some of those other things didn’t do it for me
[Participant #4]
Figure 2. Pre-postexposure NRS score differentials by intervention. NRS: Numerical Rating Scale.
View this figure
Table 3. Key themes emerging from Interviews (numbers=number of separate responses).
Major themeSubtheme (positive)Subtheme (negative)
VR designRelaxation (7)Relaxation anxiety (3)

Interaction (17)
Immersion (3)

Variety (6)

Enjoyment (4)

EfficacyEffective (14)Ineffective (4)

Distraction (8)Transient (10)

Mobility (2)Stressful (3)
Technological functionalityComfort (1)Frustration (13)

Technical issues (12)

Graphics quality (4)

Comfort (2)
Practicality-Side effects:
Cybersickness (6)
Claustrophobia (1)

Engagement (5)

Position (3)

However, 3 participants favored the relaxing experiences as in:

…some programs were really good like the guided meditation one I found really good, managed to make me feel really relaxed by the end of it.
[Participant #9]

There appeared no relationship between the type of VR experience people preferred and types of pain they experienced.

The second theme related to the efficacy of the VR experiences in helping reduce pain. Four of those interviewed identified positive benefits during the VR experience:

when I was doing them I didn’t notice the pain until I was done. So, when I play the games, no pain. But when I filled-in the questionnaire, that’s when I noticed it!
[participants #1, 4, 8, and 10]

Participants who experienced positive effects, distraction was frequently highlighted as the rationale:

So overall as an experience, if the idea is a distraction to the pain, yeah it worked for a little while then.
[Participant #4]
…actually take your mind off the world, cause you’re in a totally different place, a fantasy.
[Participant #10]

All the participants who found benefits, all reported the experience was transient and did not persist long after the VR experience:

The effect on my pain wore off and I was aware of my pain certainly within a few hours of using the VR.
[Participant #1]

Two participants reported the VR experiences were not effective for helping reduce their pain:

Overall I would just say it was really interesting, versus like actually helping with my pain.
[Participant #11]

One participant (#10) who had reported positive effects with some of the VR experiences noted one actually caused her stress, increasing her pain:

Where I was under water in the ocean, I saw the shark, and I thought it was going to attack me. It was giving me anxiety a bit, and stressing me out a bit, so as soon as I saw that my hand started burning, and my feet…
[Participant 10]

Although conversely, another acknowledged:

Some were more stressful…but I find that - when I get stress my pain doesn’t increase…
[Participant #11]

The technological functionality (and limits) of the available VR experiences also emerged as noteworthy. Four participants identified that they became quite frustrated with the VR systems in use, because of complex or cumbersome control systems:

I had some trouble figuring out which controls to use to move around so um I’ve never played computer games before and maybe that had something to do with it. I felt like a total idiot totally frustrated and not able to catch onto what to do.
[Participant #8]

The comfort of the HMD drew both positive and negative comments. One user believed that the HMD was “…nice and comfortable it was relatively small.” (Participant #1), whereas 2 others complained about issues trying to use the HMD with eyeglasses:

It was a bit uncomfortable working with my glasses.
[Participant #4]

Similarly, another theme on the practicality of using VR was evident. The side effect of cybersickness was significant and reported by 5 of the 8 participants (60%) for a least one VR experience in the self-reporting forms, and it also arose as a topic of interest in the interviews:

There was a few times where I had to stop because I felt sick because of how fast I felt I was going.
[Participant #11]

Most of the responses noted mild nausea being induced when experiences involved rapid speed or motion, or moving in 3 dimensions (such as in the spacecraft simulator), which was resolved when they slowed the experience down or had a break. However, 1 participant noted the symptoms persisted for some time after the VR experience:

I slowed down so I felt a little less bad and I thought I could continue. But afterwards I went and my mom got me a ginger ale, and I laid down and I thought, thank goodness I don’t have that in the car or whatever.
[Participant #11]

Two participants also noted minor claustrophobia as a side effect:

I felt a bit of claustrophobia because when I was under water and I realized at first I didn’t know how to get above the water and was running out of air.
[Participant #4]

The issue of being able to engage with a VR experience when the participant was experiencing severe pain also arose as a practical limitation. In 2 cases, they reported they were in too much pain to use the VR equipment.

Principal Findings

Although there were no significant pre-post exposure changes in the reported pain scores, more than half (5 of 8) of the participants did report positive benefits on their perceived pain from the use of VR. However, 3 of the participants interviewed reported none. The effects of VR on chronic pain would appear to be very individualized. No evidence that any benefits of using the VR on the participant’s pain persisted postexposure was found. For participants who identified positive results, distraction was described as the mode of action by them. This is consistent with other researchers who suggest the deeper form of distraction produced with VR experiences is the main mechanism by which pain is attenuated [19,20,22,31,46].

Chronic pain patients respond in very individualistic ways to VR as indicated by the varying preferences for interactive versus relaxing forms of VR reported. Some had very negative reactions to the relaxation introversion-focused experiences, whereas others enjoyed them. This finding is consistent with work that reports some individuals are actually relaxation-sensitive and paradoxically find relaxing experiences increase their stress levels [47,48]. Although no significant improvement in BPI and functionality was evident over time, one of the participants did report improved mobility following the VR experiences. Functional improvement has also been reported in other VR studies [49-51].

It was evident that VR technology remains immature in the technology life cycle, the progression from research and development, commercial production, to succession by superior technologies [52,53]. Most participants reported some technical issues with either the hardware or software during the experience. However, the possibility of achieving nonpharmacological pain relief may encourage more chronic pain suffering to experiment with VR, as they are more likely to experiment when pharmacological and other medical therapies fail [54,55].

The most significant adverse reaction to VR was cybersickness, as 60% of the participants experienced this at some time during the study. This side effect of VR is well documented, but should not be underestimated as a factor that may influence uptake [28,39-41,56-59]. Other than cybersickness, no significant adverse effects were noted.


As an initial exploratory study, this work has limitations. Case series are vulnerable to selection bias and may not represent the wider population, and with small-scale studies such as this, the effects seen may be due to intervening effects such as the placebo, Hawthorne, or Rosenthal effect. Therefore, internal validity and reliability may be limited. Technological immaturity of the experimental setting is also a limitation. Strengths of the study include the inductive ID approach, which is more responsive to clinical experience-based questions here. Furthermore, an exploratory pilot study provides an appropriate approach at this fundamental stage of clinical research to inform future work.

Work in this area is in its infancy and clinical studies limited. The complexities of chronic pain make finding pain-management solutions challenging, and the results reflect those complexities. The following conclusions were drawn from the results:

Exposure to VR for 30 min a day every other day for chronic pain patients in self-administered therapy sessions resulted in:

  • 66% of participants reporting a reduction in pain while using the VR therapy,
  • No significant pre- or postexposure differential in pain scores,
  • No significant postexposure impact on pain levels,
  • No significant postexposure impact on pain interfering with daily function,
  • 60% of patients reported episodes of cybersickness when using VR.

The majority of this study participants reported a reduction in pain while they were using the VR, but with highly individualized responses. Findings, as with other recent work suggests that VR maybe a useful short-term adjunct for the management of chronic pain, but individual choice in the form of VR experience may be as significant as the VR medium itself [60]. Although statistically significant reductions in pain scores postexposure were not demonstrated, in the qualitative analysis, participants reported mostly positive impacts on their pain experience, and one reported that the VR experience did appear to improve their mobility. Whereas longer-term benefits of VR therapy as an adjunctive for chronic pain were not demonstrated, the immediate relief experienced by patients here during VR would indicate the therapy has potential for a means of providing respite from the constant pain they experience.


Attention to practical implementation is important, particularly having good orientation practices and technical support available to patients at home. Robust controlled trials with larger samples, comparing VR with other forms of multimedia and neurological studies are now required to establish efficacy. Practical methods to research VR interventions should include both active and passive interventions, and larger cohort studies including assessment of cybersickness (and factors that ameliorate its effects) as the most significant adverse effect.

In conclusion, home-based VR therapy is a feasible option for chronic pain sufferers. There remains a pressing need for non-opioid alternatives in the treatment of chronic pain, and in light of the patient’s experiences documented here, individual tailored VR solutions would appear more likely to be successful compared with a unidimensional off-the-shelf VR experience.


The Helen Shore Nursing Endowment Fund is acknowledged for providing the funding to conduct the study. Pain BC and the BC People in Pain Network are acknowledged for assisting in the recruitment of patients for the study. Unknown Worlds is acknowledged for supporting the work by providing their Subnautica VR software at no cost for the research, but was not involved in the data analysis, data interpretation, or in the preparation of this manuscript.

Conflicts of Interest

None declared.

  1. Rheingold H. Virtual Reality. London: Simon & Schuster; 1991:24-28.
  2. Garrett B, Taverner T, Masinde W, Gromala D, Shaw C, Negraeff M. A rapid evidence assessment of immersive virtual reality as an adjunct therapy in acute pain management in clinical practice. Clin J Pain 2014 Dec;30(12):1089-1098. [CrossRef] [Medline]
  3. Guo C, Deng H, Yang J. Effect of virtual reality distraction on pain among patients with hand injury undergoing dressing change. J Clin Nurs 2015 Jan;24(1-2):115-120. [CrossRef] [Medline]
  4. Maani CV, Hoffman HG, Morrow M, Maiers A, Gaylord K, McGhee LL, et al. Virtual reality pain control during burn wound debridement of combat-related burn injuries using robot-like arm mounted VR goggles. J Trauma 2011 Jul;71(1 Suppl):S125-S130 [FREE Full text] [CrossRef] [Medline]
  5. JahaniShoorab N, Ebrahimzadeh Z, Nahvi A, Mazluom S, Golmakani N, Talebi M, et al. The effect of virtual reality on pain in primiparity women during episiotomy repair: a randomize clinical trial. Iran J Med Sci 2015 May;40(3):219-224 [FREE Full text] [Medline]
  6. Villiger M, Bohli D, Kiper D, Pyk P, Spillmann J, Meilick B, et al. Virtual reality-augmented neurorehabilitation improves motor function and reduces neuropathic pain in patients with incomplete spinal cord injury. Neurorehabil Neural Repair 2013 Oct;27(8):675-683. [CrossRef] [Medline]
  7. Walker MR, Kallingal GJ, Musser JE, Folen R, Stetz MC, Clark JY. Treatment efficacy of virtual reality distraction in the reduction of pain and anxiety during cystoscopy. Mil Med 2014 Aug;179(8):891-896. [CrossRef] [Medline]
  8. Jones T, Moore T, Rose H, Choo J. The impact of virtual reality on chronic pain. J Pain 2016 Apr;17(4S):S102-S103. [CrossRef] [Medline]
  9. Botella C, Garcia-Palacios A, VizYcaíno Y, Herrero R, Baños RM, Belmonte M. Virtual reality in the treatment of fibromyalgia: a pilot study. Cyberpsychol Behav Soc Netw 2013 Mar;16(3):215-223. [CrossRef] [Medline]
  10. Ramachandran V, Seckel E. Using mirror visual feedback and virtual reality to treat fibromyalgia. Med Hypotheses 2010 Dec;75(6):495-496. [CrossRef] [Medline]
  11. Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Res Manag 2011;16(6):445-450 [FREE Full text] [Medline]
  12. Smith BH, Elliott AM, Hannaford PC, Royal College of General Practitioners' Oral Contraception Study. Is chronic pain a distinct diagnosis in primary care? Evidence arising from the Royal College of General Practitioners' Oral Contraception study. Fam Pract 2004 Feb;21(1):66-74. [Medline]
  13. IASP. IASP. 2012. International Association for the Study of Pain (IASP) Taxonomy   URL: [accessed 2017-04-14] [WebCite Cache]
  14. Canadian Pain Coalition (CPC). 2014. The Painful Truth: The state of pain management in Canada   URL: [accessed 2017-04-14] [WebCite Cache]
  15. Rashiq S, Schopflocher D, Taenzer P, Jonsson E. The Economics of Chronic Pain. In: Chronic Pain. Weinheim, Germany: Wiley-Blackwell; Sep 2008:41-56.
  16. Smith BH, Elliott AM, Hannaford PC, Royal College of General Practitioners' Oral Contraception Study. Is chronic pain a distinct diagnosis in primary care? Evidence arising from the Royal College of General Practitioners' Oral Contraception study. Fam Pract 2004 Feb;21(1):66-74. [Medline]
  17. Gilmour H. Chronic pain, activity restriction and flourishing mental health. Health Rep 2015 Jan;26(1):15-22 [FREE Full text] [Medline]
  18. Gatchel R, Peng Y, Peters M, Fuchs P, Turk D. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull 2007 Jul;133(4):581-624. [CrossRef] [Medline]
  19. Sander WS, Eshelman D, Steele J, Guzzetta CE. Effects of distraction using virtual reality glasses during lumbar punctures in adolescents with cancer. Oncol Nurs Forum 2002;29(1):E8-E15. [CrossRef] [Medline]
  20. Schneider S, Prince-Paul M, Allen M, Silverman P, Talaba D. Virtual reality as a distraction intervention for women receiving chemotherapy. Oncol Nurs Forum 2004;31(1):81-88. [CrossRef] [Medline]
  21. Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965 Nov 19;150(3699):971-979. [Medline]
  22. McCaul KD, Malott JM. Distraction and coping with pain. Psychol Bull 1984 May;95(3):516-533. [Medline]
  23. Melzack R. Evolution of the neuromatrix theory of pain. 2004 May Presented at: The Prithvi Raj Lecture: The third World Congress of the World Institute of Pain; 2004; Barcelona, Spain p. 85-94.
  24. Bantick SJ, Wise RG, Ploghaus A, Clare S, Smith SM, Tracey I. Imaging how attention modulates pain in humans using functional MRI. Brain 2002 Feb;125(Pt 2):310-319. [Medline]
  25. Gold J, Belmont K, Thomas D. The neurobiology of virtual reality pain attenuation. Cyberpsychol Behav 2007 Aug;10(4):536-544. [CrossRef] [Medline]
  26. Mura G. The Meditation Chamber. In: Metaplasticity in Virtual Worlds: Aesthetics and Semantic Concepts. Hershey, PA: IGI Global; 2010:133-156.
  27. Shaw C, Gromala D, Seay AF. The meditation chamber: enacting autonomic senses. 2007 Nov Presented at: Enactive 07; November 19-22, 2007; Grenoble, France   URL:
  28. LaViola J. A discussion of cyber-sickness in virtual environments. SIGCHI Bulletin 2000;32(1):47-55 [FREE Full text]
  29. Zeidan F, Vago DR. Mindfulness meditation-based pain relief: a mechanistic account. Ann N Y Acad Sci 2016 Jun;1373(1):114-127. [CrossRef] [Medline]
  30. de Boer MJ, Steinhagen HE, Versteegen GJ, Struys MM, Sanderman R. Mindfulness, acceptance and catastrophizing in chronic pain. PLoS One 2014;9(1):e87445 [FREE Full text] [CrossRef] [Medline]
  31. Soltani M, Teeley AM, Wiechman SA, Jensen MP, Sharar SR, Patterson DR. Virtual reality hypnosis for pain control in a patient with gluteal hidradenitis: a case report(). Contemp Hypn Integr Ther 2011;28(2):142-147 [FREE Full text] [Medline]
  32. Elkins G, Johnson A, Fisher W. Cognitive hypnotherapy for pain management. Am J Clin Hypn 2012 Apr;54(4):294-310. [CrossRef] [Medline]
  33. Breivik EK, Björnsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain 2000 Mar;16(1):22-28. [Medline]
  34. Herr KA, Spratt K, Mobily PR, Richardson G. Pain intensity assessment in older adults: use of experimental pain to compare psychometric properties and usability of selected pain scales with younger adults. Clin J Pain 2004;20(4):207-219. [Medline]
  35. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994 Mar;23(2):129-138. [Medline]
  36. Sawatzky BJ, Slobogean GP, Reilly CW, Chambers CT, Hol AT. Prevalence of shoulder pain in adult- versus childhood-onset wheelchair users: a pilot study. J Rehabil Res Dev 2005;42(3 Suppl 1):1-8 [FREE Full text] [Medline]
  37. Stroud M, Turner J, Jensen M, Cardenas D. Partner responses to pain behaviors are associated with depression and activity interference among persons with chronic pain and spinal cord injury. J Pain 2006 Feb;7(2):91-99. [CrossRef] [Medline]
  38. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 2005 Mar;6(3):149-158. [CrossRef] [Medline]
  39. Bonato F, Bubka A, Palmisano S. Combined pitch and roll and cybersickness in a virtual environment. Aviat Space Environ Med 2009 Nov;80(11):941-945. [Medline]
  40. Ling Y, Brinkman WP, Nefs HT, Quo C, Heynderickx I. Cyber-sickness anxiety in virtual environments. 2011 Presented at: VTT Symposium (Valtion Teknillinen Tutkimuskeskus); 2011; Delft, Netherlands   URL: http:/​/repository.​​islandora/​object/​uuid:1f5fff10-ce0d-4fef-9c74-896f169535e9/​datastream/​OBJ/​view
  41. McCauley M, Sharkey T. Cybersickness: perception of self-motion in virtual environments. Presence-Teleop Virt 1992 Jan;1(3):311-318 [FREE Full text] [CrossRef]
  42. Thorne S, Kirkham SR, MacDonald-Emes J. Interpretive description: a noncategorical qualitative alternative for developing nursing knowledge. Res Nurs Health 1997 Apr;20(2):169-177. [Medline]
  43. Thorne S, Sandelowski M. Interpretive Description (Developing Qualitative Inquiry). Walnut Creek, CA: Left Coast Press; 2008.
  44. Davis M, Addis M. Predictors of attrition from behavioral medicine treatments. Ann Behav Med 1999;21(4):339-349. [Medline]
  45. Turk DC, Rudy TE. Neglected factors in chronic pain treatment outcome studies--referral patterns, failure to enter treatment, and attrition. Pain 1990 Oct;43(1):7-25. [Medline]
  46. Wolitzky K, Fivush R, Zimand E, Hodges L, Rothbaum B. Effectiveness of virtual reality distraction during a painful medical procedure in pediatric oncology patients. Psychol Health 2005 Dec;20(6):817-824 [FREE Full text] [CrossRef]
  47. Heide F, Borkovec T. Relaxation-induced anxiety: mechanisms and theoretical implications. Behav Res Ther 1984;22(1):1-12. [Medline]
  48. Luberto C. Thesis. Cincinnati, OH: University of Cincinnati; 2012. Development and Validation of the Relaxation Sensitivity Index   URL: [accessed 2017-04-14] [WebCite Cache]
  49. Cole J, Crowle S, Austwick G, Slater D. Exploratory findings with virtual reality for phantom limb pain; from stump motion to agency and analgesia. Disabil Rehabil 2009;31(10):846-854. [CrossRef] [Medline]
  50. van Twillert B, Bremer M, Faber A. Computer-generated virtual reality to control pain and anxiety in pediatric and adult burn patients during wound dressing changes. J Burn Care Res 2007;28(5):694-702. [CrossRef] [Medline]
  51. Thomas J, France C, Applegate M, Leitkam S, Pidcoe P, Walkowski S. Effects of visual display on joint excursions used to play virtual dodgeball. JMIR Serious Games 2016 Sep 15;4(2):e16 [FREE Full text] [CrossRef] [Medline]
  52. Bayus B. An analysis of product lifetimes in a technologically dynamic industry. Management Sci 1998;44(6):775 [FREE Full text]
  53. Rogers E. Diffusion of Innovations, 5th edition. New York, NY: Free Press; 2003.
  54. Astin J. Why patients use alternative medicine: results of a national study. JAMA 1998 May 20;279(19):1548-1553. [Medline]
  55. Thorne S, Paterson B, Russell C, Schultz A. Complementary/alternative medicine in chronic illness as informed self-care decision making. Int J Nurs Stud 2002 Sep;39(7):671-683. [Medline]
  56. Fernandes A, Feiner S. Combating VR sickness through subtle dynamic field-of-view modification. 2016 Presented at: IEEE Symposium on 3D User Interfaces (3DUI); 2016; Greenville, SC p. 201-210   URL:
  57. Kolasinski E. DTIC. 1995. Simulator sickness in virtual environments   URL: [accessed 2017-04-14] [WebCite Cache]
  58. Barrett J. Semanticscholar. Edinburgh, Australia: Australian Department of Defense; 2004. Side effects of virtual environments: a review of the literature   URL: [accessed 2017-04-14] [WebCite Cache]
  59. Merhi O, Faugloire E, Flanagan M, Stoffregen T. Motion sickness, console video games, and head-mounted displays. Hum Factors 2007 Oct;49(5):920-934. [CrossRef] [Medline]
  60. Mosadeghi S, Reid M, Martinez B, Rosen B, Spiegel Brennan Mason Ross. Feasibility of an immersive virtual reality intervention for hospitalized patients: an observational cohort study. JMIR Ment Health 2016 Jun 27;3(2):e28 [FREE Full text] [CrossRef] [Medline]

FOV: field of view
HMD: head-mounted display
VR: virtual reality
NRS: Numerical Rating Scale
S-LANSS: Self-completed Leeds Assessment of Neuropathic Symptoms and Signs pain scale

Edited by G Eysenbach; submitted 05.01.17; peer-reviewed by C Lalloo, T Jones; comments to author 23.02.17; revised version received 01.03.17; accepted 18.03.17; published 11.05.17


©Bernie Garrett, Tarnia Taverner, Paul McDade. Originally published in JMIR Medical Informatics (, 11.05.2017.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Medical Informatics, is properly cited. The complete bibliographic information, a link to the original publication on, as well as this copyright and license information must be included.